• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

强化化疗和生长因子动员后外周血干细胞采集

Peripheral blood stem cell collection after mobilization with intensive chemotherapy and growth factors.

作者信息

Dicke K A, Hood D, Hanks S

机构信息

Arlington Cancer Center, TX 76012.

出版信息

J Hematother. 1994 Summer;3(2):141-4. doi: 10.1089/scd.1.1994.3.141.

DOI:10.1089/scd.1.1994.3.141
PMID:7522898
Abstract

Peripheral blood has become an alternative to bone marrow as a source of stem cells for transplantation. One of the major disadvantages of peripheral blood as a source is the low concentration of stem cells. For successful engraftment, the infusion of at least 6 x 10(8) nucleated cells per kg is required, a cell number obtained by 6-8 cell pheresis sessions. This cell number contains approximately 0.1% CD34 cells equivalent to 600,000 CD34 cells. It is known that chemotherapy and hematopoietic growth factors increase the concentration and total number of progenitor cells in the peripheral blood. In breast and lung cancer patients we are using two cytoreductive regimens: cytoxan 2 g/m2 + platinol 90 mg/m2, and VP-16 600-900 mg/m2+ platinol 90 mg/m2, respectively, in conjunction with G-CSF for stem cell mobilization. At the time of hematopoietic recovery, between day 13 and 16, the absolute number of CD34+ cells increases in 75% of the patients more than 20-fold, from 5,000 to at least 100,000/ml blood, and to more than 40-fold, to 200,000/ml, in 54% of the patients. Therefore, 3.4-7.5 ml blood contains up to 750,000 CD34+ cells, the minimum number of CD34 cells/kg body weight infused when steady-state collected peripheral blood cells are used. Since we use a minimum of 3 x 10(6) CD34+ cells/kg body weight, 15,000 ml of mobilized blood are required. This amount can often be obtained by collecting 500 ml blood by phlebotomy in 2-3 separate sessions, which is an easy and cost-effective method for the patient.

摘要

外周血已成为骨髓的替代物,作为移植用干细胞的来源。外周血作为来源的一个主要缺点是干细胞浓度低。为实现成功植入,每千克体重至少需要输注6×10⁸个有核细胞,这个细胞数量需通过6至8次细胞单采获得。这个细胞数量包含约0.1%的CD34细胞,相当于600,000个CD34细胞。已知化疗和造血生长因子可增加外周血中祖细胞的浓度和总数。在乳腺癌和肺癌患者中,我们正在使用两种细胞减灭方案:分别是环磷酰胺2 g/m² + 顺铂90 mg/m²,以及依托泊苷600 - 900 mg/m² + 顺铂90 mg/m²,并联合使用粒细胞集落刺激因子进行干细胞动员。在造血恢复时,即第13至16天,75%的患者CD34⁺细胞绝对数量增加超过20倍,从每毫升血液5,000个增加到至少100,000个,54%的患者增加超过40倍,达到每毫升200,000个。因此,3.4至7.5毫升血液含有多达750,000个CD34⁺细胞,这是使用稳态采集的外周血细胞时每千克体重输注的CD34细胞的最少数量。由于我们使用每千克体重至少3×10⁶个CD34⁺细胞,所以需要15,000毫升动员后的血液。这个量通常可以通过在2至3个单独的采血过程中每次采集500毫升血液获得,这对患者来说是一种简单且经济有效的方法。

相似文献

1
Peripheral blood stem cell collection after mobilization with intensive chemotherapy and growth factors.强化化疗和生长因子动员后外周血干细胞采集
J Hematother. 1994 Summer;3(2):141-4. doi: 10.1089/scd.1.1994.3.141.
2
Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.巨核细胞祖细胞的体外扩增:多种生长因子组合对来自骨髓和粒细胞集落刺激因子动员的外周血的CD34+祖细胞的影响。
Exp Hematol. 1997 Oct;25(11):1125-39.
3
The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .粒细胞集落刺激因子在外周血祖细胞和干细胞动员及移植中的作用
Cytokines Mol Ther. 1995 Dec;1(4):249-70.
4
Growth factors mobilize CXCR4 low/negative primitive hematopoietic stem/progenitor cells from the bone marrow of nonhuman primates.生长因子可从非人类灵长类动物的骨髓中动员CXCR4低表达/阴性的原始造血干细胞/祖细胞。
Biol Blood Marrow Transplant. 2004 Oct;10(10):681-90. doi: 10.1016/j.bbmt.2004.07.002.
5
Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.通过化疗和粒细胞集落刺激因子(G-CSF)联合动员乳腺癌患者外周血祖细胞(PBPC)以及未处理全血采集的可能性。
Bone Marrow Transplant. 1998 Jan;21(2):123-6. doi: 10.1038/sj.bmt.1701058.
6
Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.影响原始和定向造血祖细胞动员至癌症患者外周血的因素。
Bone Marrow Transplant. 1994 Dec;14(6):877-84.
7
Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies.淋巴恶性肿瘤患者中与祖造血干细胞成功动员相关的因素。
Clin Lymphoma Myeloma. 2008 Apr;8(2):106-10. doi: 10.3816/CLM.2008.n.012.
8
Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.化疗联合或不联合重组人粒细胞集落刺激因子对外周血干细胞的动员作用
J Hematother. 1992 Winter;1(4):317-27. doi: 10.1089/scd.1.1992.1.317.
9
Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood.从人骨髓、外周血和脐带血中获取、鉴定及培养CD34+细胞。
Blood Cells. 1994;20(2-3):411-23.
10
[Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].[多发性骨髓瘤患者造血干细胞动员方案的优化]
Ter Arkh. 2011;83(7):50-7.

引用本文的文献

1
Characteristics of the PI3K/AKT and MAPK/ERK pathways involved in the maintenance of self-renewal in lung cancer stem-like cells.PI3K/AKT 和 MAPK/ERK 通路在维持肺癌干细胞自我更新中的特征。
Int J Biol Sci. 2021 Mar 15;17(5):1191-1202. doi: 10.7150/ijbs.57871. eCollection 2021.
2
Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors.衰老与造血。对造血生长因子治疗的启示。
Drugs Aging. 1996 Jul;9(1):37-47. doi: 10.2165/00002512-199609010-00004.
3
Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer.
人卵巢癌中CD44剪接变体的免疫组织化学和血清学评估
Br J Cancer. 1995 Dec;72(6):1494-7. doi: 10.1038/bjc.1995.535.